Literature DB >> 8255359

Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.

F Marzatico1, C Café, M Taborelli, G Benzi.   

Abstract

The effects of the Parkinsonism induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were evaluated in four different monkey brain areas (frontal and occipital cortex, caudate putamen, substantia nigra). The basal and stimulated lipid peroxidation and the reduced glutathione (GSH) concentration were evaluated in three groups of male Macaca fascicularis monkeys (6 animals/group): (a) controls; (b) MPTP-treated animals; (c) animals treated with MPTP and alpha-dihydroergocryptine (DEK; ergot alkaloid characterized by a dopaminergic agonist action). In MPTP-treated animals the GSH concentration was unchanged or decreased in a non-significant way in the frontal and occipital cortex, and in substantia nigra. The basal thiobabituric acid reactive substance (TBARS) concentrations were significantly higher in the caudate putamen and substantia nigra of MPTP-treated animals. In the MPTP-treated monkeys the DEK administration induced a restoration of basal TBARS values to nearly normal ones. By incubating tissue from different brain areas with FeSO4 plus ascorbic acid, the stimulation of lipid peroxidation decreased the TBARS production in the substantia nigra of the MPTP-treated animals. These results, taken together, may indicate that an increased lipid peroxidation could possibly play a role in producing the Parkinson-like syndrome by MPTP and that a free radical excess could be responsible for the degeneration of the substantia nigra. The treatment with an ergot alkaloid (i.e., alpha-dihydroergocryptine) partially antagonizes the MPTP-induced increase in basal TBARS concentration in caudate putamen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255359     DOI: 10.1007/bf00966691

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  33 in total

1.  Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects.

Authors:  J N Johannessen; C C Chiueh; R S Burns; S P Markey
Journal:  Life Sci       Date:  1985-01-21       Impact factor: 5.037

2.  Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.

Authors:  D T Dexter; C J Carter; F R Wells; F Javoy-Agid; Y Agid; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

3.  Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  A Barbeau; M Roy; J W Langston
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

4.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro.

Authors:  Z L Rossetti; A Sotgiu; D E Sharp; M Hadjiconstantinou; N H Neff
Journal:  Biochem Pharmacol       Date:  1988-12-01       Impact factor: 5.858

5.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

6.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

7.  The mitochondrial electron transfer alteration as a factor involved in the brain aging.

Authors:  G Benzi; O Pastoris; F Marzatico; R F Villa; F Dagani; D Curti
Journal:  Neurobiol Aging       Date:  1992 May-Jun       Impact factor: 4.673

8.  Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse.

Authors:  H Hallman; L Olson; G Jonsson
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

9.  Influence of aging and drug treatment on the cerebral glutathione system.

Authors:  G Benzi; O Pastoris; F Marzatico; R F Villa
Journal:  Neurobiol Aging       Date:  1988 Jul-Aug       Impact factor: 4.673

10.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment.

Authors:  V W Yong; T L Perry; A A Krisman
Journal:  Neurosci Lett       Date:  1986-01-02       Impact factor: 3.046

View more
  4 in total

1.  Striatal metabolism of hexanal, a lipid peroxidation product, in the rat.

Authors:  V Jaar; L Ste-Marie; J A Montgomery
Journal:  Metab Brain Dis       Date:  1999-06       Impact factor: 3.584

2.  Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models.

Authors:  Jie Zhou; Xiao-Dong Qu; Zhi-Yun Li; Qi Liu; Yi-Hui Ma; Jiao-Jiang He
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

3.  Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson's disease.

Authors:  Masoumeh Dadgar; Mahdi Pouramir; Zohreh Dastan; Maryam Ghasemi-Kasman; Manouchehr Ashrafpour; Ali Akbar Moghadamnia; Soraya Khafri; Mohsen Pourghasem
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec

4.  Matrix augmentation as an efficient method for resolving interaction of bromocriptine with human serum albumin: trouble shooting and simultaneous resolution.

Authors:  Ali R Jalalvand; Sirous Ghobadi; Hector C Goicoechea; Elahe Faramarzi; Majid Mahmoudi
Journal:  Heliyon       Date:  2019-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.